A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...

Guest writer Kylene Henderson's husband had just been diagnosed with PF when they decided to take a family road trip to ...

Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

Columnist Samuel Kirton has nothing but praise for caregivers, who represent the best of what is right in the world.

Columnist Samuel Kirton had to put a plan in place after his lung transplant to make sure his drinking water was safe for him to consume.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

Hyperbaric oxygen therapy can counteract some of the key features of pulmonary fibrosis (PF) in mice and human lung cells, a recent study reveals. The findings suggest this treatment, involving the ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...